pinkslipjunkie
4 days ago
Reformation Agreement of the Share Exchange Agreement with Resonate Blends, Inc.
As previously disclosed in a previous Disclosure Report, Resonate Blends, Inc., a Nevada corporation (the
โResonateโ), Resonate entered into entered into a Share Exchange Agreement (the โExchange Agreementโ) with
Emergent Health Corp., a Wyoming corporation (โEMGEโ), and the holders (collectively, the โEMGE Preferred
Shareholdersโ) of Series Class A Preferred Stock and the Series C Convertible Non-Voting Preferred Stock
(collectively, the โEMGE Equity Interestsโ). On March 14, 2024, the parties closed the Exchange Agreement.
At the closing of the Exchange Agreement: (a) the EMGE Preferred Shareholders exchanged all of their
respective EMGE Equity Interests for an equal number of shares of Resonateโs Series F Convertible Preferred
Stock that converts into 93% of the common stock of the Company on a fully-diluted basis (the โResonate
Exchange Sharesโ), which shares of Series F Preferred Stock are currently issuable to the EMGE Preferred
Shareholders and are to be issued upon the Resoanteโs filing of a Certificate of Designation with the State of
Nevada; (b)Resonate consummated a conveyance agreement; and (c) all persons serving as directors and officers
of the Resonate prior to the consummation of the Exchange Agreement resigned and appointed four new members
of the Resoanteโs Board of Directors.
Effective August 8, 2024, Resoante entered into a Reformation of Share Exchange Agreement (the
โReformation Agreementโ) with EMGE and the EMGE Preferred Shareholders. The Reformation Agreement
was entered into after Resonate, EMGE and the EMGE Preferred Shareholders having independently determined
that the structure of the Exchange Agreement resulted in the partiesโ experiencing consequences that were
unintended and that would not, in the long term, be beneficial to the parties and that a reformation of the Exchange
Agreement from a share-for-share structure to a share-for-asset structure would be beneficial to each of the parties.
By the Reformation Agreement, share-for-share structure of the Exchange Agreement was reformed to
become a share-for-asset structure (the โReformationโ). Effecting the Reformation produced the following
actions (the โReformation Actionsโ):
(a) First, the issuances of the Resonate Exchange Shares to the EMGE Preferred Shareholders were
rescinded.
(b) Next, the assignments of the EMGE Equity Interests by the EMGE Preferred Shareholders to
Resonate were rescinded.
(c) Resonate, then, re-issued the Resonate Exchange Shares to EMGE, in consideration of the
following assets of EMGE (the โAcquired Assetsโ):
-All of the capital stock of Evolutionary Biologics, Inc.;
-All of the capital stock of Apollo Biowellness, Inc.;
- All of the capital stock of Nanosthetic, Inc.; and
- All of the capital stock of Nanogistics, Inc.
pinkslipjunkie
4 days ago
As stated in the KOAN 10-Q:
On February 26, 2024, the Company entered into entered into a Share Exchange Agreement, as amended (the โExchange Agreementโ), with Emergent Health Corp., a Wyoming corporation (EMGE), and the holders (the โEMGE Preferred Shareholdersโ) of Series Class A Preferred Stock and the Series C Convertible Non-Voting Preferred Stock (the โEMGE Equity Interestsโ). On March 14, 2024, the parties closed the Exchange Agreement. At the closing of the Exchange Agreement: (a) the EMGE Preferred Shareholders exchanged all of their respective EMGE Equity Interests for an equal number of shares of the Companyโs to-be-designated Series F Convertible Preferred Stock (the โExchange Sharesโ) that shall convert into 93% of the common stock of the Company on a fully-diluted basis (the โSeries F Preferred Stockโ), which shares of Series F Preferred Stock are currently issuable to the EMGE Preferred Shareholders and are to be issued upon the Companyโs filing of a Certificate of Designation with the State of Nevada; (b) the Company consummated the Conveyance Agreement; and (c) all persons serving as directors and officers of the Company prior to the consummation of the Exchange Agreement resigned and appointed four new members of the Companyโs Board of Directors.
pinkslipjunkie
4 days ago
As you were saying...no change in the share structure and no dilution as first illustrated in the quarterly report:
As of November 26, 2024, the number of shares outstanding of our Common Stock was:
426,951,112 common shares issued and outstanding.
As of November 26, 2024, the number of shares outstanding of our Series A Preferred Stock was:
100 shares issued and outstanding.
As of November 26, 2024, the number of shares outstanding of our Series B Preferred Stock was:
20,500,000 common shares issued and outstanding.
As of November 26, 2024, the number of shares outstanding of our Series C Preferred Stock was:
20.000.000 shares issued and outstanding.
As of November 26, 2024, the number of shares outstanding of our Series F Preferred Stock was:
1,000 common shares issued and outstanding.
compare to 2023
As of December 31, 2023, the number of shares outstanding of our Common Stock was:
426,951,112 common shares issued and outstanding.
As of December 31, 2023, the number of shares outstanding of our Series A Preferred Stock was:
100 shares issued and outstanding.
As of December 31, 2023, the number of shares outstanding of our Series B Preferred Stock was:
20,500,000 common shares issued and outstanding.
As of December 31, 2023, the number of shares outstanding of our Series C Preferred Stock was:
20.000.000 shares issued and outstanding.
paulie c
3 weeks ago
September 30, 2024
After a month-long jury trial, on Friday, September 27, Arnold & Porter achieved a resounding victory for client Cynosure from a unanimous Boston jury in the United States District Court, District of Massachusetts, resulting in an award of over $25 million in compensatory and punitive damages.
Cynosure, a leading provider of aesthetic and medical treatment devices, had filed a lawsuit against industry competitor Reveal Lasers and 28 employees for breaching contracts and duties of loyalty, as well as engaging in tortious interference with contractual relations, trade secret misappropriation, unfair and deceptive trade practices, and conspiracy. The firm achieved victories at several key stages โ including obtaining a temporary restraining order within days of the cases being filed and then a preliminary injunction, with the court (Judge Patti Saris) enforcing a number of the noncompetes.
Gatorca
3 weeks ago
Had to ask AI about that, if it would affect the Joint Venture/Partnership with EvoBio. I'm not worried at all lol...
AI answer... The recent lawsuit involving Reveal Lasers and the misappropriation of trade secrets from Cynosure is unlikely to directly affect the joint venture between Apollo Biowellness, Inc. and Reveal Lasers LLC. The partnership is focused on expanding the distribution and collaboration of Evo Bio Products, which are biologic solutions for aesthetic and regenerative health1.
However, it's important to note that legal disputes can sometimes create uncertainties and affect business relationships. Apollo Biowellness, Inc. will likely monitor the situation closely to ensure that their interests are protected.
Ops forgot this part... so why didnt reveal lose there license to practice?
Reveal Lasers LLC hasn't lost its license to practice because the legal issues primarily involved corporate espionage, breach of contract, and misappropriation of trade secrets, rather than violations that would typically result in the revocation of a medical or business license. Regulatory bodies often focus on patient safety and compliance with medical standards when considering license revocations. Since the lawsuit was a (Civil Matter) between two companies, it didn't directly impact Reveal Lasers' operational licenses.
powerbattles
4 weeks ago
The share structure was updated yesterday and remains unchanged. Thereโs been no dilution in the past 18 months. DTC holds 220 million shares, leaving a very small float for a stock currently trading at $0.0012.
Outstanding Shares
426,951,112
11/06/2024
Restricted
134,427,516
11/06/2024
Unrestricted
292,523,596
11/06/2024
Held at DTC
220,620,568
11/06/20https://www.otcmarkets.com/stock/EMGE/security24